CAR-T cell therapy in AML did not show the same success as seen in ALL, and the target of CAR T-cells in AML was CD123 and CD33; the latter was used in treating a patient and showed a significant reduction in tumor volume in the bone marrow; however, 9 weeks post-infusion, the patient experienced a relapse (Wang et al., 2015). This evidence concerns the gene CD33 and acute myeloid leukemia.